Results 151 to 160 of about 3,320,695 (338)
How to: Surveillance of Clostridium difficile infections.
M. Krutova+5 more
semanticscholar +1 more source
Extra-intestinal infections caused by Clostridium difficile [PDF]
J.M. Garcáa-Lechuz+5 more
openalex +1 more source
Grape Seed Proanthocyanidins: A Potential Microbiome‐Targeted Intervention for Healthy Aging in Rats
Grape seed proanthocyanidin extract (GSPE) promotes a healthier gut phenotype in aged rats. Aging alters gut microbiota composition, increases inflammation, and compromises intestinal barrier function. This study shows that short‐term GSPE treatment in aged rats partially restores microbial diversity toward a youthful profile, modulates mucus‐related ...
Marta Sierra‐Cruz+10 more
wiley +1 more source
Ureidopenicillins and risk of Clostridium difficile infection [PDF]
Jane Freeman, Mark H. Wilcox
openalex +1 more source
Extracellular vesicles from Lactobacillus plantarum improved lipid metabolism in HFD‐fed mice by regulating hepatic genes involved in lipid synthesis and oxidation. They also alleviated intestinal dysfunction by reducing inflammation, enhancing barrier function, and modulating gut microbiota and metabolites, underscoring their therapeutic potential in ...
Shan‐Shan Xu+8 more
wiley +1 more source
Diagnosis of Clostridium difficile Infections in Children
Stella Antonara, A. Leber
semanticscholar +1 more source
Clostridium difficile: Infection and Immunity
Clostridium difficile is a Gram positive pathogen of significant importance in the UK, Europe and the USA. No vaccine has been developed and current treatments are focused on hospital management and the use of antibiotics. The disease is spread in hospitals in the spore form and the role of spores in C. difficile infecton is poorly understood.
openaire +7 more sources
Infection of Hamsters with Epidemiologically Important Strains ofClostridium difficile [PDF]
Susan P. Sambol+4 more
openalex +1 more source
ABSTRACT Background Combining immune checkpoint inhibitors (ICI) with chemotherapy may improve treatment response in children with solid tumors. We sought to determine the feasibility of combining vincristine, irinotecan, and temozolomide with the ICI atezolizumab in children with relapsed or refractory solid tumors (VITAS;). Methods Patients ≥6 months
Matthew E. Campbell+16 more
wiley +1 more source